An engineered stem cell remedy reversed new-onset Sort 1 diabetes in mice by shifting the immune system away from attacking insulin-producing cells.
For greater than a century, folks with Sort 1 diabetes have relied on insulin to outlive, however the therapy doesn’t cease the immune system from persevering with its assault on the physique’s insulin-producing cells. Scientists have lengthy searched for tactics to handle the underlying explanation for the illness relatively than merely managing its signs.
Now, researchers on the Medical College of South Carolina (MUSC) report an experimental stem cell remedy that reversed newly identified Sort 1 diabetes in a mouse mannequin. The therapy, described in Molecular Remedy, was designed to reprogram the immune system and shield the insulin-producing cells that stay after illness onset, providing a possible new technique for combating the autoimmune dysfunction.
The work was led by Hongjun Wang, Ph.D., affiliate director of the South Carolina Scientific & Translational Analysis (SCTR) Institute Pilot Program and co-scientific director of the Heart for Mobile Remedy. Co-first authors Hua Wei, Ph.D.; Judong Kim, Ph.D.; and Wenyu Gou, Ph.D., along with different collaborators, carried out a lot of the analysis behind the findings.
“Whereas insulin injections are lifesaving, they can not cease immune assaults, and they don’t forestall long-term problems,” stated Wang. “This examine suggests a brand new technique to deal with Sort 1 diabetes by addressing the basis trigger – immune system dysfunction –relatively than simply managing blood sugar.”
The remedy is predicated on mesenchymal stem/stromal cells (MSCs), grownup stem cells that may assist restore tissue and regulate immune exercise. Earlier medical trials have advised that commonplace MSCs could assist protect the insulin manufacturing that is still in folks with T1D. The problem is that the physique’s intense inflammatory response can overpower these cells earlier than they can reverse established illness.
To make the cells extra resilient, Wang’s group engineered MSCs to supply alpha-1 antitrypsin (AAT), a protecting protein that helps defend in opposition to irritation. The modified AAT-MSCs seem to work in two methods directly, defending surviving insulin-producing cells within the pancreas whereas additionally lowering the overactive immune assault. Co-senior creator Charlie Unusual, M.D., emphasised that this mixed impact makes AAT-MSC therapy stronger than commonplace stem cell remedy.
Reprogramming the immune system
Wang’s group subsequent investigated how the therapy was performing contained in the immune system. After inspecting hundreds of particular person immune cells, they discovered that AAT-MSC infusion did greater than quiet an overactive immune response. It appeared to reshape how the immune system behaved.
The remedy impacts two opposing immune cell teams. T-regulatory cells act as peacekeepers, serving to protect insulin manufacturing within the pancreas, whereas CD8+ killer T-cells drive the assault that destroys insulin-producing cells. In T1D, the protecting cells are current, however they’re overwhelmed by a continuing wave of attacking cells, which finally contributes to the lack of insulin manufacturing.
After therapy with AAT-MSCs, Wang and her group noticed a pointy rise within the variety of protecting T-regulatory cells and a drop in lively attacking cells. These attacker cells appeared to have been pushed into exhaustion by the remedy.
One other notable function of the therapy was its sturdiness. The stem cells disappeared from the physique inside hours or days, but the immune system modifications continued.
“To affect or remedy T1D, the stem cells themselves do not must be there,” stated Wang. “Which means while you administer the cell remedy to sufferers, the impact can final six months to 2 years, as seen in medical trials utilizing MSCs for a spread of ailments.” Wang thinks AAT-MSCs could launch microscopic elements that preserve defending organs after the cells themselves are gone.
A hopeful future
The examine centered on newly identified diabetes, a interval when sufferers usually tend to nonetheless have insulin-producing cells that may probably be saved. The Wang group is now evaluating the protection and effectiveness of MSCs in sufferers with newly identified Sort 1 diabetes in a medical trial. Wang’s earlier work on this space was supported by a SCTR Discovery Grant.
The findings might have relevance past diabetes. Wang and her colleagues are already learning whether or not an analogous immune reprogramming method might be helpful for different inflammatory and autoimmune ailments, together with lupus and continual pancreatitis.
Extra analysis continues to be wanted earlier than this therapy can advance into broader medical testing, however the outcomes level to a doable new course for diabetes care.
“If preliminary trials are profitable, we wish to do a big, multicenter trial for Sort 1 diabetes,” stated Wang. “The excellent news is that there are research saying that even when you’ve got had T1D for a few years, you continue to have remaining insulin-producing cells there which can be functioning. So hopefully we are able to apply this to folks with long-term T1D as effectively.”
Reference: “Taming autoimmunity: Alpha-1 antitrypsin overexpressing mesenchymal stromal cells promote regulatory T cell crosstalk to reverse diabetes” by Hua Wei, Wenyu Gou, Judong Kim, Suganya Subramanian, Tiffany Yeung, Paramita Chakraborty, Ahmed Lotfy, Shikhar Mehrotra, Stefano Berto, Charlie Unusual and Hongjun Wang, 30 March 2026, Molecular Remedy.
DOI: 10.1016/j.ymthe.2026.03.032
